Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28008497 | 0.98 | KMT2A (0.47) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL1031714 | 0.87 | YTHDF2 (0.46) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL28298685 | 0.80 | ALDH1A1 (0.50) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL28207016 | 0.79 | ALDH1A1 (0.49) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL8182458 | 0.76 | KMT2A (0.45) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL1946240 | 0.76 | KMT2A (0.61) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL1945206 | 0.74 | ALDH1A1 (0.42) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL28298686 | 0.74 | ALDH1A1 (0.42) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL6027678 | 0.73 | TYMP (0.46) | KMT2AALDH1A1MEN1LMNAYTHDF2 | |
| SCHEMBL1945172 | 0.73 | KMT2A (0.58) | KMT2AL3MBTL1ALDH1A1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-4547747-A1 | POLYOXMETHYLENE POLYMER INCORPORATING AN ALDEHYDE SCAVENGER | Colormatrix Holdings, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-119156419-A | Polyoxymethylene polymers containing aldehyde scavengers | 彩色矩阵控股公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024003633-A1 | POLYOXMETHYLENE POLYMER INCORPORATING AN ALDEHYDE SCAVENGER | COLORMATRIX HOLDINGS, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| US-20230312809-A1 | LIQUID FORMULATION COMPRISING AN ALDEHYDE SCAVENGER | Ferline SA (CH) | 2023-10-05 | — | — | US | claimed |
| EP-4157915-A1 | LIQUID FORMULATION COMPRISING AN ALDEHYDE SCAVENGER | Ferline SA (CH) | 2023-04-05 | — | — | EP | claimed |
| CN-115698118-A | Liquid formulations comprising aldehyde scavengers | 佛莱恩股份公司 | 2023-02-03 | — | — | CN | claimed |
| US-11400042-B2 | Process for treating keratin fibres, comprising the application of a composition comprising urea or a derivative thereof, a polyol and an amino silicone | L'OREAL (FR) | 2022-08-02 | — | — | US | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1999031124-A1 | CHOLIC ACID-BASED SCAFFOLDS FOR MULTIDIMENSIONAL MOLECULAR PRESENTATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 1999-06-24 | — | — | WO | claimed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400042-B2 | Process for treating keratin fibres, comprising the application of a composition comprising urea or a derivative thereof, a polyol and an amino silicone | KRT18, CUTA, PUF60 | KMT2A 1413/4885L3MBTL1 4022/4885ALDH1A1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.